Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia.


6617 Background: 101M is a new alkylating agent with broad activity in murine tumor models, including alkylator-resistant L1210 leukemia. In a phase I single agent study of relapsed/refractory (R/R) leukemias, the MTD was 600 mg/m2, the DLT was prolonged myelosuppression, and 2/38 pts achieved a complete remission (CR). The current phase I trial will… (More)